Ανακοίνωση - Πρόσκληση
Το Δι-Ιδρυματικό Μεταπτυχιακό Πρόγραμμα Σπουδών
(ΔΠΜΣ Τμήματος Χημείας και Ινστιτούτου Βιοεπιστημών & Εφαρμογών ΕΚΕΦΕ “Δημόκριτος”)
Εφαρμοσμένη Βιοχημεία:
Κλινική Χημεία, Βιοτεχνολογία & Αξιολόγηση Φαρμακευτικών Προϊόντων
στο πλαίσιο του
"Κύκλου σεμιναρίων προσκεκλημένων ομιλητών"
που διοργανώνει
την Πέμπτη 3 Φεβρουαρίου 2022 και ώρα 13:00 (12 CET)
σας προσκαλεί στη διαδικτυακή διάλεξη της
Prof. Liliana Schaefer
Institute of Pharmacology, Goethe University, Frankfurt/Main, Germany
με θέμα:
Interplay of biglycan with its receptors in inflammation and autophagy
σε σύνδεση μέσω zoom:
https://upatras-gr.zoom.us/j/5583501511?pwd=M2cyNjdWMFdQeEFjSVpsb1NZWDgzQT09
________________________________________
Announcement - Invitation
The Postgraduate Program
(Joint Postgraduate Programme of the Department of Chemistry and the Institute of Biosciences and Applications of NCSR "Demokritos”)
Applied Biochemistry:
Clinical Chemistry, Biotechnology & Evaluation of Pharmaceutical Products
in the context of
"Seminars of invited speakers"
invites you to her online lecture on
Thursday, February 3rd, 2022 at 12:00 CET
Prof. Liliana Schaefer
Institute of Pharmacology, Goethe University, Frankfurt/Main, Germany
on the subject:
Interplay of biglycan with its receptors in inflammation and autophagy
online zoom:
https://upatras-gr.zoom.us/j/5583501511?pwd=M2cyNjdWMFdQeEFjSVpsb1NZWDgzQT09
______________________________________________________
Short cv: Liliana Schaefer, MD, is a Professor of Pharmacology at the Institute of Pharmacology and Toxicology, Goethe University in Frankfurt, Germany and Adjunct Research Professor of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, USA. Dr. Schaefer has made significant contributions to the field of proteoglycans by discovering that two components of the extracellular matrix, Decorin and Biglycan, act as endogenous danger signals. Currently Dr. Schaefer is the President of the Histochemical Society, the Editor-in-Chief of the American Journal of Physiology-Cell Physiology, the member of the FASEB publication committee, and the Chair of the Gordon Research Conference on Proteoglycans 2022.
Short talk description: It is well established that biglycan, a small leucine-rich proteoglycan, acts as an extracellular matrix-derived danger signal in its soluble form. By binding to innate immunity Toll-like receptors (TLR) 2 and 4, biglycan initiates and perpetuates the inflammatory response. Previous work has conveyed that biglycan's role in inflammation extends far beyond its function as a canonical danger signal. Mounting evidence suggests that the selective interactions between biglycan, TLRs, and their adapter proteins critically regulate downstream signaling and disease outcome. Biglycan can act as a high-affinity ligand for TLR coreceptors CD14 and CD44, further providing an additional layer of complexity. We propose a novel concept, that biglycan steers signaling toward inflammation by interacting with CD14, whereas it can trigger autophagy by binding to CD44. Thus, biglycan, and perhaps others soluble proteoglycans, could function as molecular switches which could either propagate the signaling of chronic inflammation or promote the resolution of inflammatory processes.
